Shilpa Medicare -Racing away on the Oncology API highway!

(Sandeep Patel) #326

Shilpa Medicare Q3 results.

Financial Highlights (consolidated)

  • Revenue up by 28% YoY from 154.50 cr to 198.24 cr
  • EBITA up by ~8% YoY from 28.28 cr to 30.44 cr
  • Net Profit up by 65% YoY from 16.93 cr to 28 cr (driven by lower tax 48% YoY from 11.25cr to 5.74cr!!)


Congratulations to the management team and we minority shareholders for the USFDA approval (API sites) and a good set of quarterly numbers.

(Krishnendu) #327

What I would like to know will there be any adverse impact on Shilpa or Natco for this new rule made by govt to withdraw exemption in import.

(Jagadish) #328

Any impact or disruption for Shilpa Medicare’s business?

(nabendu) #329

Another news on similar line ~
Though all these developments are at a very initial stage (at least 3~4 years away of commercial virtue), disruption in traditional cancer treatment is imminent. We, as a shareholder hope Shilpa gets USFDA approval of formulation unit early enough and the company delivers on its potential.

(Sandeep Patel) #330

We would need to see how the vaccine succeeds (personally, would wish it succeeds). It is in trial stage; to run over the next two years involving up to 30 volunteers. At end of the day it has to be effective, safe, versatile and commercially viable. Will have to wait and see.

As Hiteshbhai says “There is a huge deluge of newsflows on almost all companies and one needs to prioritize what is important and what is not” (for now).

Till then, let’s enjoy the joker in the pack (USFDA approval). The single biggest risk factor is behind us. Cheers.

(vivek naik) #331

depending heavily on just one branch of medecine is always a risk for any pharma co , would prefer to be in businesses that are diversified across major verticals.immunotherapy is making steady progress in the fight against cancer but is yet to be commercialised.

(Rakesh ) #332

Shilpa Medicare Ltd has informed BSE that the Company received GMP compliance certificate for two API sites (Unit-1: Deosugur Industrial Area, Deosugur-584170, Raichur, Karnataka, India; Unit-2: Plot nos. 33, 33A, 40 to 47, Raichur Industrial growth Centre, Wadloor Road, Chicksugur-584134, Raichur, Karnataka, India) from PMDA-Japan.


Is it possible to get any guesstimate on revenue from current flurry of FDA approvals?

(Ankit Gupta) #334

The March quarter ending DMF filing list with USFDA is out and Shilpa has filed two DMFs (including one filed in December which got recorded in this quarter’s filing) taking its total tally of DMF filed to 26 now. The details are given below:

  • AXITINIB (gInlyta, innovator - Pfizer): Filed on December 24, 2015. Exclusivity expiry - Jan 27, 2017 Patent expiry - June 30, 2020. gInlyta is a prescription medicine used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC) when one prior drug treatment for this disease has not worked or has stopped working. DMF Filers - Three including MSN Laboratories and Zhejing Jiuzou Pharmaceutical Co Ltd. In CY’15, US Sales of USD 205 million and worldwide sales of USD 430 million. Just three filers currently for DMF and moderate size molecule.
  • ENZALUTAMIDE (gXtandi, innovator - Astellas): Filed on March 17, 2016. Exclusivity Expiry - September 10, 2017 & Patent Expiry - May 15, 2026. Used for treatment of prostrate cancer. DMF Filers - Six including Sai Lifescience Ltd, DRL, Cadila, Mylan and MSN. US Sales of around USD 900 million and world wide sales of USD 1.50 billion. Seems to be a blockbuster products but no clarity on the date of generic launch as no Para IV filing yet.

(Sandeep Patel) #335

Shilpa Q4 and FY16 numbers are out and predictably very good.


Disc: Invested

(Rakesh ) #336


In terms of ROE or its expansion it is not very good and negative on incremental return by way of profits. I am perplexed what could be the reason for this. Is it a red flag. Natco is far ahead in this measure.

(casambhav) #338

Shilpa Medicare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on June 27, 2016, inter alia, to consider a proposal of merger of Navya Boilogicals Private Limited with the Company.

Navya Biologicals Private Limited (“NBPL”) is a company incorporated under the Companies Act, is engaged on research and development activities in the field of biologicals. NBPL has specifically been in the development of bio-similars and product process technologies.

(aravindms1us) #339

Arrow Greentech has filed a suit on Shilpa / Nu Therapeutics

(Saji John) #340

Promoters have increased their stake by 3.84% @BSE latest share holding pattern.


That looks like increase by way of gifts within family. Sr. members gifting to new generation.

(Piyush) #342

ShilpaMed 2016072.pdf (324.9 KB)

Detailed report on Shilpa by ICICI securities.

(Rajesh) #343

Successful USFDA audit completed for formulations facility at Jadcherla.

(Abhishek Basumallick) #345

(Sandeep Patel) #346

10% YoY type growth reported in Q1FY17. Normally, the first quarter is soft for Shilpa.